Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Simon Smith"'
Autor:
Young Suk Park, Peter G. Mortimer, Kyoung-Mee Kim, Sophie E. Willis, Emma Dean, Claire Smith, Jung Yong Hong, Itziar Irurzun-Arana, Arsene-Bienvenu Loembé, Joon Oh Park, Iwanka Kozarewa, Andrew J. Pierce, Jeeyun Lee, Ho Yeong Lim, Simon Smith, Alienor Berges, Won Ki Kang, Hee Jin Cho, Seung Tae Kim, Se Hoon Park
Publikováno v:
Clinical Cancer Research. 27:4700-4709
Purpose: Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein. Patients and Methods: Eligible patients with solid tumors, enriched for melanoma, received cer
Publikováno v:
International Journal of Infectious Diseases, Vol 102, Iss, Pp 132-135 (2021)
Introduction Clinicians are commonly taught that if patients with suspected rickettsial disease have continuing fever after 48 hours of anti-rickettsial therapy, an alternative diagnosis is likely. Methods This retrospective study of patients hospita
Publikováno v:
IDCases, Vol 23, Iss, Pp e01015-(2021)
IDCases
IDCases
A 57-year-old Australian woman, with a history of hazardous alcohol consumption, presented with a seizure following 2 days of fever and headache. Initial imaging suggested the presence of an isolated brain abscess, however, a thorough physical examin
Publikováno v:
IDCases, Vol 21, Iss, Pp e00833-(2020)
IDCases
IDCases
We report the case of a 61-year-old man from northern Australia with concurrent community-onset Acinetobacter baumannii complex and Burkholderia pseudomallei bacteremia presenting as severe tropical pneumonia requiring intensive care unit support. Th
Autor:
Martin Forster, Kabir Mohammed, Glen Clack, Clare Peckitt, Simon Smith, Kevin J. Harrington, James Spicer, Udai Banerji, Magnus T. Dillon, J. Guevara, Mark P Saunders, Z. Boylan, D. Smith
Publikováno v:
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, Vol 12, Iss, Pp 16-20 (2018)
Clinical and Translational Radiation Oncology, Vol 12, Iss, Pp 16-20 (2018)
Highlights • Summary of a protocol for a phase I study combining the ATR inhibitor and palliative radiotherapy. • Study design is discussed. • Study aims and objectives, brief eligibility criteria, DLT criteria and dose escalation is discussed.
Publikováno v:
Pathology. 48:639-642
Mycoplasma pneumoniae remains a common cause of community acquired respiratory tract infections in adults and children. To provide empirical coverage against M. pneumoniae, doxycycline or a macrolide combined with a β-lactam is considered the most a
Autor:
Z. Boylan, J. Guevara, James Spicer, Martin Forster, L. McLellan, Magnus T. Dillon, K.J. Harrington, Kabir Mohammed, Emma Dean, Simon Smith
Publikováno v:
Annals of Oncology. 30:v165-v166
Background ATR inhibition (ATRi) exploits high levels of replication stress and G1/S cell cycle checkpoint dysfunction frequently seen in cancers, increasing DNA damage and inducing mitotic crisis. ATRi may also potentiate DNA-damaging anticancer the
Autor:
Suzanne S. Poulgrain, Yu-Hsuan Liu, Alexis Dermedgoglou, Simon Smith, Josh Hanson, Matthew P. Paavola, Michael Luc, Tarryn L. Minto, Brendan Kennedy
Publikováno v:
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Vol 13, Iss 2, p e0007205 (2019)
PLoS Neglected Tropical Diseases, Vol 13, Iss 2, p e0007205 (2019)
Background The case-fatality rate of severe leptospirosis can exceed 50%. While prompt supportive care can improve survival, predicting those at risk of developing severe disease is challenging, particularly in settings with limited diagnostic suppor
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
Autor:
Manish R. Patel, Suzanne F. Jones, Jay Yang, Julie Charlton, William B. Donnellan, Ehab Atallah, Philip Overend, Jon Travers, Simon Smith, Giulia Fabbri, J. Elizabeth Pease, Carrie A. Adelman, Alexander MacDonald, Donald K. Strickland, Elizabeth Sainsbury, Gautam Borthakur, Adam S. Asch, Alireza Eghtedar, Jan Cosaert, Anna Korzeniowska
Publikováno v:
Blood. 134:3919-3919
Background: Aurora kinases (AurK) represent potential targets for anticancer therapy in hematological malignancies and solid tumors. AurK B inhibitor AZD1152 (barasertib) showed benefit (35% CR/CRi) in patients (pts) with untreated AML when given as